Nuclear receptors in regenerating liver and hepatocellular carcinoma

Molecular and Cellular Endocrinology

Volumn 368, Issue 1-2, 2013, Pages 108-119

  Vacca, Michele ^a,b,c   Degirolamo, Chiara ^a   Massafra, Vittoria ^a   Polimeno, Lorenzo ^d   Mariani Costantini, Renato ^a,b   Palasciano, Giuseppe ^c   Moschetta, Antonio ^a,c,d,e  

^a Laboratory of Lipid Metabolism and Cancer   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

^e NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

Liver; Molecular biology; Nuclear receptors

Indexed keywords

ANTIESTROGEN; BIOLOGICAL MARKER; CELL NUCLEUS RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FARNESOID X RECEPTOR; GLUCOCORTICOID RECEPTOR; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; ORAL CONTRACEPTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PREGNANE X RECEPTOR; RETINOID X RECEPTOR; ROSIGLITAZONE; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

CANCER HORMONE THERAPY; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; LIVER REGENERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; BILE ACIDS AND SALTS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GENE EXPRESSION REGULATION; HEPATOCYTES; HUMANS; LIPIDS; LIVER NEOPLASMS; LIVER REGENERATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 84875245371     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.06.025     Document Type: Review

References (169)

1. Alison M.R., Poulsom R., Jeffery R., Dhillon A.P., Quaglia A., Jacob J., Novelli M., Prentice G., Williamson J., Wright N.A. Hepatocytes from non-hepatic adult stem cells. Nature 2000, 406:257.
2. Anderson S.P., Yoon L., Richard E.B., Dunn C.S., Cattley R.C., Corton J.C. Delayed liver regeneration in peroxisome proliferator-activated receptor-alpha-null mice. Hepatology 2002, 36:544-554.
3. Barish G.D., Narkar V.A., Evans R.M. PPAR delta: a dagger in the heart of the metabolic syndrome. J. Clin. Invest 2006, 116:590-597.
4. Bensinger S.J., Bradley M.N., Joseph S.B., Zelcer N., Janssen E.M., Hausner M.A., Shih R., Parks J.S., Edwards P.A., Jamieson B.D., Tontonoz P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008, 134:97-111.
5. Bookout A.L., Jeong Y., Downes M., Yu R.T., Evans R.M., Mangelsdorf D.J. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 2006, 126:789-799.
6. Bralet M.P., Branchereau S., Brechot C., Ferry N. Cell lineage study in the liver using retroviral mediated gene transfer. Evidence against the streaming of hepatocytes in normal liver. Am. J. Pathol. 1994, 144:896-905.
7. Braun L., Mikumo R., Fausto N. Production of hepatocellular carcinoma by oval cells: cell cycle expression of c-myc and p53 at different stages of oval cell transformation. Cancer Res. 1989, 49:1554-1561.
8. Brown M.S., Goldstein J.L. Suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and inhibition of growth of human fibroblasts by 7-ketocholesterol. J. Biol. Chem. 1974, 249:7306-7314.
9. Calkin A.C., Tontonoz P. Liver x receptor signaling pathways and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1513-1518.
10. Chan D.W., Chan C.Y., Yam J.W., Ching Y.P., Ng I.O. Prickle-1 negatively regulates Wnt/beta-catenin pathway by promoting Dishevelled ubiquitination/degradation in liver cancer. Gastroenterology 2006, 131:1218-1227.
11. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294:1866-1870.
12. Chen A., Xu J. Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G447-G456.
13. Chen H.W., Kandutsch A.A., Waymouth C. Inhibition of cell growth by oxygenated derivatives of cholesterol. Nature 1974, 251:419-421.
14. Chen W., Chen G., Head D.L., Mangelsdorf D.J., Russell D.W. Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab. 2007, 5:73-79.
15. Chen W.D., Wang Y.D., Meng Z., Zhang L., Huang W. Nuclear bile acid receptor FXR in the hepatic regeneration. Biochim. Biophys. Acta 2011, 1812:888-892.
16. Chen W.D., Wang Y.D., Zhang L., Shiah S., Wang M., Yang F., Yu D., Forman B.M., Huang W. Farnesoid X receptor alleviates age-related proliferation defects in regenerating mouse livers by activating forkhead box m1b transcription. Hepatology 2010, 51:953-962.
17. Chiang K.C., Yeh C.N., Chen M.F., Chen T.C. Hepatocellular carcinoma and vitamin D: a review. J. Gastroenterol. Hepatol. 2011, 26:1597-1603.
18. Collino M., Aragno M., Castiglia S., Miglio G., Tomasinelli C., Boccuzzi G., Thiemermann C., Fantozzi R. Pioglitazone improves lipid and insulin levels in overweight rats on a high cholesterol and fructose diet by decreasing hepatic inflammation. Br. J. Pharmacol. 2010, 160:1892-1902.
19. Columbano A., Ledda-Columbano G.M., Pibiri M., Concas D., Reddy J.K., Rao M.S. Peroxisome proliferator-activated receptor-alpha mice show enhanced hepatocyte proliferation in response to the hepatomitogen 1,4-bis[2-(3,5-dichloropyridyloxy)] benzene, a ligand of constitutive androstane receptor. Hepatology 2001, 34:262-266.
20. Columbano A., Shinozuka H. Liver regeneration versus direct hyperplasia. FASEB J. 1996, 10:1118-1128.
21. Costa R.H., Kalinichenko V.V., Tan Y., Wang I.C. The CAR nuclear receptor and hepatocyte proliferation. Hepatology 2005, 42:1004-1008.
22. Dai G., He L., Bu P., Wan Y.J. Pregnane X receptor is essential for normal progression of liver regeneration. Hepatology 2008, 47:1277-1287.
23. De Benedetti V.M., Welsh J.A., Yu M.C., Bennett W.P. p53 Mutations in hepatocellular carcinoma related to oral contraceptive use. Carcinogenesis 1996, 17:145-149.
24. Degirolamo C., Modica S., Palasciano G., Moschetta A. Bile acids and colon cancer: solving the puzzle with nuclear receptors. Trends Mol. Med. 2011, 17:564-572.
25. Derynck R., Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003, 425:577-584.
26. Devchand P.R., Keller H., Peters J.M., Vazquez M., Gonzalez F.J., Wahli W. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 1996, 384:39-43.
27. Di M.M., Daniele B., Pignata S., Gallo C., De M.E., Morabito A., Piccirillo M.C., Perrone F. Is human hepatocellular carcinoma a hormone-responsive tumor?. World J. Gastroenterol. 2008, 14:1682-1689.
28. Doffoel M., Bonnetain F., Bouche O., Vetter D., Abergel A., Fratte S., Grange J.D., Stremsdoerfer N., Blanchi A., Bronowicki J.P., Caroli-Bosc F.X., Causse X., Masskouri F., Rougier P., Bedenne L. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Federation Francophone de Cancerologie Digestive 9402). Eur. J. Cancer 2008, 44:528-538.
29. Dreyer C., Krey G., Keller H., Givel F., Helftenbein G., Wahli W. Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992, 68:879-887.
30. Duncan A.W., Dorrell C., Grompe M. Stem cells and liver regeneration. Gastroenterology 2009, 137:466-481.
31. Dupont S., Krust A., Gansmuller A., Dierich A., Chambon P., Mark M. Effect of single and compound knockouts of estrogen receptors alpha (ERalpha) and beta (ERbeta) on mouse reproductive phenotypes. Development 2000, 127:4277-4291.
32. Erol E., Kumar L.S., Cline G.W., Shulman G.I., Kelly D.P., Binas B. Liver fatty acid binding protein is required for high rates of hepatic fatty acid oxidation but not for the action of PPARalpha in fasting mice. FASEB J. 2004, 18:347-349.
33. Falleti E., Bitetto D., Fabris C., Cussigh A., Fontanini E., Fornasiere E., Fumolo E., Bignulin S., Cmet S., Minisini R., Pirisi M., Toniutto P. Vitamin D receptor gene polymorphisms and hepatocellular carcinoma in alcoholic cirrhosis. World J. Gastroenterol. 2010, 16:3016-3024.
34. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
35. Fausto N. Lessons from genetically engineered animal models. V. Knocking out genes to study liver regeneration: present and future. Am. J. Physiol. 1999, 277:G917-G921.
36. Fausto N., Campbell J.S., Riehle K.J. Liver regeneration. Hepatology 2006, 43:S45-S53.
37. Fellous T.G., Islam S., Tadrous P.J., Elia G., Kocher H.M., Bhattacharya S., Mears L., Turnbull D.M., Taylor R.W., Greaves L.C., Chinnery P.F., Taylor G., McDonald S.A., Wright N.A., Alison M.R. Locating the stem cell niche and tracing hepatocyte lineages in human liver. Hepatology 2009, 49:1655-1663.
38. Fernandez, C., Lobo, M.M.V., Gomez-Coronado, D., Lasuncion, M.A., 2004. Cholesterol is essential for mitosis progression and its deficiency induces polyploid cell formation. Exp. Cell Res. 300, 109-120.
39. Field F.J., Mathur S.N., LaBrecque D.R. Cholesterol metabolism in regenerating liver of the rat. Am. J. Physiol. 1985, 249:G679-G684.
40. Friedman J.R., Kaestner K.H. On the origin of the liver. J. Clin. Invest. 2011, 121:4630-4633.
41. Fruchart J.C. Novel peroxisome proliferator activated receptor-alpha agonists. Am. J. Cardiol. 2007, 100:n41-n46.
42. Fujita T. Evolution of the lectin-complement pathway and its role in innate immunity. Nat. Rev. Immunol. 2002, 2:346-353.
43. Fukuchi J., Kokontis J.M., Hiipakka R.A., Chuu C.P., Liao S. Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells. Cancer Res. 2004, 64:7686-7689.
44. Furuyama K., Kawaguchi Y., Akiyama H., Horiguchi M., Kodama S., Kuhara T., Hosokawa S., Elbahrawy A., Soeda T., Koizumi M., Masui T., Kawaguchi M., Takaori K., Doi R., Nishi E., Kakinoki R., Deng J.M., Behringer R.R., Nakamura T., Uemoto S. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat. Genet. 2011, 43:34-41.
45. Galli A., Ceni E., Mello T., Polvani S., Tarocchi M., Buccoliero F., Lisi F., Cioni L., Ottanelli B., Foresta V., Mastrobuoni G., Moneti G., Pieraccini G., Surrenti C., Milani S. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin. Hepatology 2010, 52:493-505.
46. Geier A., Dietrich C.G., Voigt S., Kim S.K., Gerloff T., Kullak-Ublick G.A., Lorenzen J., Matern S., Gartung C. Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 2003, 38:345-354.
47. Germain P., Chambon P., Eichele G., Evans R.M., Lazar M.A., Leid M., De Lera A.R., Lotan R., Mangelsdorf D.J., Gronemeyer H. International union of pharmacology. LXIII. Retinoid X receptors. Pharmacol. Rev. 2006, 58:760-772.
48. Giannelli G., Bergamini C., Fransvea E., Sgarra C., Antonaci S. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 2005, 129:1375-1383.
49. Goldstein J.L., Brown M.S. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. J. Biol. Chem. 1974, 249:5153-5162.
50. Gonzalez F.J., Shah Y.M. PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 2008, 246:2-8.
51. Heinrich P.C., Behrmann I., Haan S., Hermanns H.M., Muller-Newen G., Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
52. Ho W.L., Wu C.C., Yeh D.C., Chen J.T., Huang C.C., Lin Y.L., Liu T.J., P'eng F.K. Roles of the glucocorticoid receptor in resectable hepatocellular carcinoma. Surgery 2002, 131:19-25.
53. Hsu M.H., Savas U., Griffin K.J., Johnson E.F. Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor alpha in HepG2 cells. J. Biol. Chem. 2001, 276:27950-27958.
54. Huang W., Ma K., Zhang J., Qatanani M., Cuvillier J., Liu J., Dong B., Huang X., Moore D.D. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006, 312:233-236.
55. Huang W., Zhang J., Washington M., Liu J., Parant J.M., Lozano G., Moore D.D. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol. Endocrinol. 2005, 19:1646-1653.
56. Imai T., Jiang M., Kastner P., Chambon P., Metzger D. Selective ablation of retinoid X receptor alpha in hepatocytes impairs their lifespan and regenerative capacity. Proc. Natl. Acad. Sci. USA 2001, 98:4581-4586.
57. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347:645-650.
58. Kalra M., Mayes J., Assefa S., Kaul A.K., Kaul R. Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World J. Gastroenterol. 2008, 14:5945-5961.
59. Kaposi-Novak P., Lee J.S., Gomez-Quiroz L., Coulouarn C., Factor V.M., Thorgeirsson S.S. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J. Clin. Invest. 2006, 116:1582-1595.
60. Karabelyos C., Dobozy O., Szalai C., Klenjanszki K., Varju K., Hadhazi A., Kiss A., Fulop A.K., Madarasz B., Falus A. Elevated hepatic glucocorticoid receptor expression during liver regeneration in rats. Pathol. Oncol. Res. 1999, 5:107-109.
61. Karas R.H., Hodgin J.B., Kwoun M., Krege J.H., Aronovitz M., Mackey W., Gustafsson J.A., Korach K.S., Smithies O., Mendelsohn M.E. Estrogen inhibits the vascular injury response in estrogen receptor beta-deficient female mice. Proc. Natl. Acad. Sci. USA 1999, 96:15133-15136.
62. Kastner P., Grondona J.M., Mark M., Gansmuller A., LeMeur M., Decimo D., Vonesch J.L., Dolle P., Chambon P. Genetic analysis of RXR alpha developmental function: convergence of RXR and RAR signaling pathways in heart and eye morphogenesis. Cell 1994, 78:987-1003.
63. Kim I., Morimura K., Shah Y., Yang Q., Ward J.M., Gonzalez F.J. Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice. Carcinogenesis 2007, 28:940-946.
64. Kodama S., Negishi M. Pregnane X receptor PXR activates the GADD45beta gene, eliciting the p38 MAPK signal and cell migration. J. Biol. Chem. 2011, 286:3570-3578.
65. Koniaris L.G., McKillop I.H., Schwartz S.I., Zimmers T.A. Liver regeneration. J. Am. Coll. Surg. 2003, 197:634-659.
66. Korula J., Yellin A., Kanel G., Campofiori G., Nichols P. Hepatocellular carcinoma coexisting with hepatic adenoma. Incidental discovery after long-term oral contraceptive use. West J. Med. 1991, 155:416-418.
67. Laconi S., Pani P., Pillai S., Pasciu D., Sarma D.S., Laconi E. A growth-constrained environment drives tumor progression in vivo. Proc. Natl. Acad. Sci. USA 2001, 98:7806-7811.
68. Lanz R.B., McKenna N.J., Onate S.A., Albrecht U., Wong J., Tsai S.Y., Tsai M.J., O'Malley B.W. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 1999, 97:17-27.
69. Lee J.S., Heo J., Libbrecht L., Chu I.S., Kaposi-Novak P., Calvisi D.F., Mikaelyan A., Roberts L.R., Demetris A.J., Sun Z., Nevens F., Roskams T., Thorgeirsson S.S. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 2006, 12:410-416.
70. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 1995, 270:12953-12956.
71. Liddle C., Farrell G.C. Role of the oestrogen receptor in liver regeneration in the male rat. J. Gastroenterol. Hepatol. 1993, 8:524-529.
72. Lien H.C., Lu Y.S., Shun C.T., Yao Y.T., Chang W.C., Cheng A.L. Differential expression of glucocorticoid receptor in carcinomas of the human digestive system. Histopathology 2008, 52:314-324.
73. Limaye P.B., Bowen W.C., Orr A., Apte U.M., Michalopoulos G.K. Expression of hepatocytic- and biliary-specific transcription factors in regenerating bile ducts during hepatocyte-to-biliary epithelial cell transdifferentiation. Comp. Hepatol. 2010, 9:9.
74. Liu N., Meng Z., Lou G., Zhou W., Wang X., Zhang Y., Zhang L., Liu X., Yen Y., Lai L., Forman B.M., Xu Z., Xu R., Huang W. Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1alpha regulation of FXR expression. Mol. Endocrinol. 2012, 26:775-785.
75. Llovet J.M., Chen Y., Wurmbach E., Roayaie S., Fiel M.I., Schwartz M., Thung S.N., Khitrov G., Zhang W., Villanueva A., Battiston C., Mazzaferro V., Bruix J., Waxman S., Friedman S.L. A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology 2006, 131:1758-1767.
76. Lo Sasso G., Celli N., Caboni M., Murzilli S., Salvatore L., Morgano A., Vacca M., Pagliani T., Parini P., Moschetta A. Down-regulation of the LXR transcriptome provides the requisite cholesterol levels to proliferating hepatocytes. Hepatology 2010, 51:1334-1344.
77. Lonard D.M., O'Malley B.W. Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation. Mol. Cell 2007, 27:691-700.
78. Luedde, T., Beraza, N., Kotsikoris, V., van, L.G., Nenci, A., De, V.R., Roskams, T., Trautwein, C., Pasparakis, M., 2007. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 11, 119-132.
79. Maheshwari S., Sarraj A., Kramer J., El-Serag H.B. Oral contraception and the risk of hepatocellular carcinoma. J. Hepatol. 2007, 47:506-513.
80. Malato Y., Naqvi S., Schurmann N., Ng R., Wang B., Zape J., Kay M.A., Grimm D., Willenbring H. Fate tracing of mature hepatocytes in mouse liver homeostasis and regeneration. J. Clin. Invest. 2011, 121:4850-4860.
81. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell 1995, 83:841-850.
82. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., Evans R.M. The nuclear receptor superfamily: the second decade. Cell 1995, 83:835-839.
83. Martinez-Botas J., Suarez Y., Ferruelo A.J., Gomez-Coronado D., Lasuncion M.A. Cholesterol starvation decreases p34(cdc2) kinase activity and arrests the cell cycle at G2. FASEB J. 1999, 13:1359-1370.
84. McKenna N.J., O'Malley B.W. Nuclear receptors, coregulators, ligands, and selective receptor modulators: making sense of the patchwork quilt. Ann. NY Acad. Sci. 2001, 949:3-5.
85. McKenna N.J., O'Malley B.W. Minireview: nuclear receptor coactivators - an update. Endocrinology 2002, 143:2461-2465.
86. Mehrotra A., Kaul D., Joshi K. LXR-alpha selectively reprogrammes cancer cells to enter into apoptosis. Mol. Cell. Biochem. 2011, 349:41-55.
87. Meng Z.X., Nie J., Ling J.J., Sun J.X., Zhu Y.X., Gao L., Lv J.H., Zhu D.Y., Sun Y.J., Han X. Activation of liver X receptors inhibits pancreatic islet beta cell proliferation through cell cycle arrest. Diabetologia. 2008, 52:125-135.
88. Michalopoulos G.K. Liver regeneration. J. Cell. Physiol. 2007, 213:286-300.
89. Michalopoulos G.K., DeFrances M.C. Liver regeneration. Science 1997, 276:60-66.
90. Milona, A., Owen, B.M., van, M.S., Dormann, D., Mataki, C., Boudjelal, M., Cairns, W., Schoonjans, K., Milligan, S., Parker, M., White, R., Williamson, C., 2010. The normal mechanisms of pregnancy-induced liver growth are not maintained in mice lacking the bile acid sensor Fxr. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G151-G158.
91. Modica S., Gadaleta R.M., Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm. Nucl. Recept. Signal. 2010, 8:e005.
92. Morimura K., Cheung C., Ward J.M., Reddy J.K., Gonzalez F.J. Differential susceptibility of mice humanized for peroxisome proliferator-activated receptor alpha to Wy-14,643-induced liver tumorigenesis. Carcinogenesis 2006, 27:1074-1080.
93. Motojima K., Passilly P., Peters J.M., Gonzalez F.J., Latruffe N. Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J. Biol. Chem. 1998, 273:16710-16714.
94. Motomura W., Takahashi N., Nagamine M., Sawamukai M., Tanno S., Kohgo Y., Okumura T. Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int. J. Cancer 2004, 108:41-46.
95. Mueller K.M., Kornfeld J.W., Friedbichler K., Blaas L., Egger G., Esterbauer H., Hasselblatt P., Schlederer M., Haindl S., Wagner K.U., Engblom D., Haemmerle G., Kratky D., Sexl V., Kenner L., Kozlov A.V., Terracciano L., Zechner R., Schuetz G., Casanova E., Pospisilik J.A., Heim M.H., Moriggl R. Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology 2011, 54:1398-1409.
96. Na T.Y., Shin Y.K., Roh K.J., Kang S.A., Hong I., Oh S.J., Seong J.K., Park C.K., Choi Y.L., Lee M.O. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2009, 49:1122-1131.
97. Newberry E.P., Kennedy S.M., Xie Y., Luo J., Stanley S.E., Semenkovich C.F., Crooke R.M., Graham M.J., Davidson N.O. Altered hepatic triglyceride content after partial hepatectomy without impaired liver regeneration in multiple murine genetic models. Hepatology 2008, 48:1097-1105.
98. Ogata H., Kobayashi T., Chinen T., Takaki H., Sanada T., Minoda Y., Koga K., Takaesu G., Maehara Y., Iida M., Yoshimura A. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology 2006, 131:179-193.
99. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., Hoffmann A., Subramaniam S., David M., Rosenfeld M.G., Glass C.K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005, 122:707-721.
100. Onate S.A., Boonyaratanakornkit V., Spencer T.E., Tsai S.Y., Tsai M.J., Edwards D.P., O'Malley B.W. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J. Biol. Chem. 1998, 273:12101-12108.
101. Otte K., Kranz H., Kober I., Thompson P., Hoefer M., Haubold B., Remmel B., Voss H., Kaiser C., Albers M., Cheruvallath Z., Jackson D., Casari G., Koegl M., Paabo S., Mous J., Kremoser C., Deuschle U. Identification of farnesoid X receptor beta as a novel mammalian nuclear receptor sensing lanosterol. Mol. Cell. Biol. 2003, 23:864-872.
102. Overturf K., Al-Dhalimy M., Finegold M., Grompe M. The repopulation potential of hepatocyte populations differing in size and prior mitotic expansion. Am. J. Pathol. 1999, 155:2135-2143.
103. Pascussi J.M., Robert A., Moreau A., Ramos J., Bioulac-Sage P., Navarro F., Blanc P., Assenat E., Maurel P., Vilarem M.J. Differential regulation of constitutive androstane receptor expression by hepatocyte nuclear factor4alpha isoforms. Hepatology 2007, 45:1146-1153.
104. Perez M.J., Briz O. Bile-acid-induced cell injury and protection. World J. Gastroenterol. 2009, 15:1677-1689.
105. Phillips J.M., Yamamoto Y., Negishi M., Maronpot R.R., Goodman J.I. Orphan nuclear receptor constitutive active/androstane receptor-mediated alterations in DNA methylation during phenobarbital promotion of liver tumorigenesis. Toxicol. Sci. 2007, 96:72-82.
106. Pibiri M., Ledda-Columbano G.M., Cossu C., Simbula G., Menegazzi M., Shinozuka H., Columbano A. Cyclin D1 is an early target in hepatocyte proliferation induced by thyroid hormone (T3). FASEB J. 2001, 15:1006-1013.
107. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
108. Ponder K.P. Analysis of liver development, regeneration, and carcinogenesis by genetic marking studies. FASEB J. 1996, 10:673-682.
109. Pourgholami M.H., Morris D.L. 1,25-Dihydroxyvitamin D3 in lipiodol for the treatment of hepatocellular carcinoma: cellular, animal and clinical studies. J. Steroid Biochem. Mol. Biol. 2004, 89-90:513-518.
110. Qin X., Xie X., Fan Y., Tian J., Guan Y., Wang X., Zhu Y., Wang N. Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice. Hepatology 2008, 48:432-441.
111. Rao M.S., Peters J.M., Gonzalez F.J., Reddy J.K. Hepatic regeneration in peroxisome proliferator-activated receptor alpha-null mice after partial hepatectomy. Hepatol. Res. 2002, 22:52-57.
112. Reddy J.K., Rao S., Moody D.E. Hepatocellular carcinomas in acatalasemic mice treated with nafenopin, a hypolipidemic peroxisome proliferator. Cancer Res. 1976, 36:1211-1217.
113. Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura I., Shan B., Brown M.S., Goldstein J.L., Mangelsdorf D.J. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors. LXRalpha and LXRbeta. Genes Dev. 2000, 14:2819-2830.
114. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
115. Rosenberg L. The risk of liver neoplasia in relation to combined oral contraceptive use. Contraception 1991, 43:643-652.
116. Rudnick D.A. Trimming the fat from liver regeneration. Hepatology 2005, 42:1001-1003.
117. Rudolph K.L., Chang S., Millard M., Schreiber-Agus N., DePinho R.A. Inhibition of experimental liver cirrhosis in mice by telomerase gene delivery. Science 2000, 287:1253-1258.
118. Sakurai T., Maeda S., Chang L., Karin M. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc. Natl. Acad. Sci. USA 2006, 103:10544-10551.
119. Sandgren E.P., Palmiter R.D., Heckel J.L., Daugherty C.C., Brinster R.L., Degen J.L. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 1991, 66:245-256.
120. Sell S., Dunsford H.A. Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma. Am. J. Pathol. 1989, 134:1347-1363.
121. Shachaf C.M., Kopelman A.M., Arvanitis C., Karlsson A., Beer S., Mandl S., Bachmann M.H., Borowsky A.D., Ruebner B., Cardiff R.D., Yang Q., Bishop J.M., Contag C.H., Felsher D.W. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004, 431:1112-1117.
122. Shah Y.M., Morimura K., Yang Q., Tanabe T., Takagi M., Gonzalez F.J. Peroxisome proliferator-activated receptor alpha regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation. Mol. Cell. Biol. 2007, 27:4238-4247.
123. Shim J., Kim B.H., Kim Y.I., Kim K.Y., Hwangbo Y., Jang J.Y., Dong S.H., Kim H.J., Chang Y.W., Chang R. The peroxisome proliferator-activated receptor gamma ligands, pioglitazone and 15-deoxy-delta(12,14)-prostaglandin J(2), have antineoplastic effects against hepatitis B virus-associated hepatocellular carcinoma cells. Int. J. Oncol. 2010, 36:223-231.
124. Sicklick J.K., Li Y.X., Jayaraman A., Kannangai R., Qi Y., Vivekanandan P., Ludlow J.W., Owzar K., Chen W., Torbenson M.S., Diehl A.M. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 2006, 27:748-757.
125. Skrtic S., Carlsson L., Ljungberg A., Linden D., Michalik L., Wahli W., Oscarsson J. Decreased expression of peroxisome proliferator-activated receptor alpha and liver fatty acid binding protein after partial hepatectomy of rats and mice. Liver Int. 2005, 25:33-40.
126. Sucov H.M., Dyson E., Gumeringer C.L., Price J., Chien K.R., Evans R.M. RXR alpha mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. Genes Dev. 1994, 8:1007-1018.
127. Tabas I. Consequences of cellular cholesterol accumulation: basic concepts and physiological implications. J. Clin. Invest. 2002, 110:905-911.
128. Takata Y., Liu J., Yin F., Collins A.R., Lyon C.J., Lee C.H., Atkins A.R., Downes M., Barish G.D., Evans R.M., Hsueh W.A., Tangirala R.K. PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis. Proc. Natl. Acad. Sci. USA 2008, 105:4277-4282.
129. Tanaka N., Moriya K., Kiyosawa K., Koike K., Gonzalez F.J., Aoyama T. PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J. Clin. Invest. 2008, 118:683-694.
130. Taub R. Hepatoprotection via the IL-6/Stat3 pathway. J. Clin. Invest. 2003, 112:978-980.
131. Taub R. Liver regeneration: from myth to mechanism. Nat. Rev. Mol. Cell Biol. 2004, 5:836-847.
132. Taub R., Greenbaum L.E., Peng Y. Transcriptional regulatory signals define cytokine-dependent and -independent pathways in liver regeneration. Semin. Liver Dis. 1999, 19:117-127.
133. Terpstra O.T., Malt R.A., Bucher N.L. Negligible role of adrenal hormones in regulation of DNA synthesis in livers of partially hepatectomized rats. Proc. Soc. Exp. Biol. Med. 1979, 161:326-331.
134. Thurman R.G., Kauffman F.C. Sublobular compartmentation of pharmacologic events (SCOPE): metabolic fluxes in periportal and pericentral regions of the liver lobule. Hepatology 1985, 5:144-151.
135. Tobin J.F., Freedman L.P. Nuclear receptors as drug targets in metabolic diseases: new approaches to therapy. Trends Endocrinol. Metab. 2006, 17:284-290.
136. Tontonoz P., Hu E., Graves R.A., Budavari A.I., Spiegelman B.M. MPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994, 8:1224-1234.
137. Tontonoz P., Mangelsdorf D.J. Liver X receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 2003, 17:985-993.
138. Tontonoz P., Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 2008, 77:289-312.
139. Toyoda M., Takagi H., Horiguchi N., Kakizaki S., Sato K., Takayama H., Mori M. A ligand for peroxisome proliferator activated receptor gamma inhibits cell growth and induces apoptosis in human liver cancer cells. Gut 2002, 50:563-567.
140. Trauner M., Halilbasic E. Nuclear receptors as new perspective for the management of liver diseases. Gastroenterology 2011, 140:1120-1125.
141. Turmelle Y.P., Shikapwashya O., Tu S., Hruz P.W., Yan Q., Rudnick D.A. Rosiglitazone inhibits mouse liver regeneration. FASEB J. 2006, 20:2609-2611.
142. Ueda J., Chijiiwa K., Nakano K., Zhao G., Tanaka M. Lack of intestinal bile results in delayed liver regeneration of normal rat liver after hepatectomy accompanied by impaired cyclin E-associated kinase activity. Surgery 2002, 131:564-573.
143. Verset G., Verslype C., Reynaert H., Borbath I., Langlet P., Vandebroek A., Peeters M., Houbiers G., Francque S., Arvanitakis M., Van Laethem J.L. Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study. Br. J. Cancer 2007, 97:582-588.
144. Wang G.L., Iakova P., Wilde M., Awad S., Timchenko N.A. Liver tumors escape negative control of proliferation via PI3K/Akt-mediated block of C/EBP alpha growth inhibitory activity. Genes Dev. 2004, 18:912-925.
145. Wang X., Foster M., Al-Dhalimy M., Lagasse E., Finegold M., Grompe M. The origin and liver repopulating capacity of murine oval cells. Proc. Natl. Acad. Sci. USA 2003, 100(Suppl. 1):11881-11888.
146. Wang Y.D., Chen W.D., Wang M., Yu D., Forman B.M., Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008, 48:1632-1643.
147. Wang Y.X. PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Res. 2010, 20:124-137.
148. Weglarz T.C., Degen J.L., Sandgren E.P. Hepatocyte transplantation into diseased mouse liver. Kinetics of parenchymal repopulation and identification of the proliferative capacity of tetraploid and octaploid hepatocytes. Am. J. Pathol. 2000, 157:1963-1974.
149. Wei P., Zhang J., Egan-Hafley M., Liang S., Moore D.D. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 2000, 407:920-923.
150. Wouters, K., van, B.M., van Gorp, P.J., Bieghs, V., Lutjohann, D., Kerksiek, A., Staels, B., Hofker, M.H., Shiri-Sverdlov, R., 2010. Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett. 584, 1001-1005.
151. Xu L., Han C., Lim K., Wu T. Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells. Cancer Res. 2006, 66:11859-11868.
152. Yamada Y., Kirillova I., Peschon J.J., Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc. Natl. Acad. Sci. USA 1997, 94:1441-1446.
153. Yamamoto Y., Moore R., Flavell R.A., Lu B., Negishi M. Nuclear receptor CAR represses TNFalpha-induced cell death by interacting with the anti-apoptotic GADD45B. PLoS One 2010, 5:e10121.
154. Yamamoto Y., Moore R., Goldsworthy T.L., Negishi M., Maronpot R.R. The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res. 2004, 64:7197-7200.
155. Yamamoto Y., Ono T., Dhar D.K., Yamanoi A., Tachibana M., Tanaka T., Nagasue N. Role of peroxisome proliferator-activated receptor-gamma (PPARgamma) during liver regeneration in rats. J. Gastroenterol. Hepatol. 2008, 23:930-937.
156. Yan Y., Xu W., Qian H., Si Y., Zhu W., Cao H., Zhou H., Mao F. Mesenchymal stem cells from human umbilical cords ameliorate mouse hepatic injury in vivo. Liver Int. 2009, 29:356-365.
157. Yang F., Huang X., Yi T., Yen Y., Moore D.D., Huang W. Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor. Cancer Res. 2007, 67:863-867.
158. Yang X., Guo M., Wan Y.J. Deregulation of growth factor, circadian clock, and cell cycle signaling in regenerating hepatocyte RXRalpha-deficient mouse livers. Am. J. Pathol. 2010, 176:733-743.
159. Youssef J., Badr M. Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br. J. Pharmacol. 2011, 164:68-82.
160. Yu J., Shen B., Chu E.S., Teoh N., Cheung K.F., Wu C.W., Wang S., Lam C.N., Feng H., Zhao J., Cheng A.S., To K.F., Chan H.L., Sung J.J. Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology 2010, 51:2008-2019.
161. Yu L., Gupta S., Xu F., Liverman A.D., Moschetta A., Mangelsdorf D.J., Repa J.J., Hobbs H.H., Cohen J.C. Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J. Biol. Chem. 2005, 280:8742-8747.
162. Yu S., Matsusue K., Kashireddy P., Cao W.Q., Yeldandi V., Yeldandi A.V., Rao M.S., Gonzalez F.J., Reddy J.K. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J. Biol. Chem. 2003, 278:498-505.
163. Yuan X., Yan S., Zhao J., Shi D., Yuan B., Dai W., Jiao B., Zhang W., Miao M. Lipid metabolism and peroxisome proliferator-activated receptor signaling pathways participate in late-phase liver regeneration. J. Proteome Res. 2011, 10:1179-1190.
164. Zabielski P., Blachnio-Zabielska A., Baranowski M., Zendzian-Piotrowska M., Gorski J. Activation of PPARalpha by bezafibrate negatively affects de novo synthesis of sphingolipids in regenerating rat liver. Prostaglandins Other Lipid Mediat. 2010, 93:120-125.
165. Zajicek G., Oren R., Weinreb M. The streaming liver. Liver 1985, 5:293-300.
166. Zelcer N., Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 2006, 116:607-614.
167. Zhang J., Huang W., Qatanani M., Evans R.M., Moore D.D. The constitutive androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced hepatotoxicity. J. Biol. Chem. 2004, 279:49517-49522.
168. Zhang Y., Gong W., Dai S., Huang G., Shen X., Gao M., Xu Z., Zeng Y., He F. Downregulation of human farnesoid X receptor by miR-421 promotes proliferation and migration of hepatocellular carcinoma cells. Mol. Cancer Res. 2012, 10:516-522.
169. Zingarelli B., Piraino G., Hake P.W., O'Connor M., Denenberg A., Fan H., Cook J.A. Peroxisome proliferator-activated receptor delta regulates inflammation via NF-{kappa}B signaling in polymicrobial sepsis. Am. J. Pathol. 2010, 177:1834-1847.